. Elimination via the lungs (after exposure) and the kidney is theoretically a small fraction of total methanol elimination (8,11) and modeled well in both rat and mouse without being specifically included (10). In both the rat and mouse, the systemic disposition of methanol was similar after oral (PO), intravenous (IV), or inhalation administration (Perkins et al., submitted).
. Investigations of methanol inhalation in laboratory rodents have indicated that high doses of methanol cause a variety of birth defects (2-7). As methanol is proposed as a motor fuel additive, the general public may be exposed to increased levels of environmental methanol, prompting recent attempts to assess the risk of the teratogenic potential of methanol in humans (8) . A (8, 11) and modeled well in both rat and mouse without being specifically included (10) . In both the rat and mouse, the systemic disposition of methanol was similar after oral (PO), intravenous (IV), or inhalation administration (Perkins et al., submitted).
To assess risk to the human conceptus based on extrapolation from rodent data, it is desirable to begin with comparisons of blood methanol concentrations rather than with the ambient methanol vapor concentration; as demonstrated in rodents, blood concentrations can vary substantially between species exposed to the same ambient methanol concentration. Blood toxicant levels are a more relevant determinant of systemic effects (such as teratogenicity) than are ambient environmental toxicant concentrations (12 (1) , the primate is the model of choice for both kinetic and toxicologic studies of methanol, and only data obtained from human and nonhuman primates in the published literature were used in this study. Numerical values presented in tables were preferred to values that were scaled from charts or graphs, although the majority of data were scaled. Many of the data were reported as methanol concentrations in urine rather than in blood. It has been shown that blood methanol concen-trations are 77% of urine methanol concentrations (13) ; similar values were reported by other investigators (8, 14) and correspond to earlier work in this laboratory (10) . Urine data reported by other investigators (15) (16) (17) for mice (average of fast and slow absorption processes); Vd = 0.85 for rats and 0.76 for mice] determined previously in this laboratory (10) .
In previous investigations, a LineweaverBurke plot based on methanol doses in the rhesus monkey 0.05-1.0 g/kg (producing blood methanol concentrations of approximately 60 to 1200 mg/L) was used to recover an apparent Km of 278 mg/L, based on Vd of 0.7 L/kg (20) . In other work, a Km of 544 mg/L for methanol was reported with the monkey ADH enzyme in vitro (26 Low dose. Groups of three or four healthy humans were exposed for 8 hr to environments of 77, 156.5, and 229 ppm methanol in air, and urine methanol concentrations were determined (22) . Figure 2 shows the estimated blood methanol concentrations in those subjects and model predictions with the parameters defined above and (D = 0.645; that value of( yielded exactly the 8-hr blood methanol concentration of the 156.5 ppm dose. Those authors also reported a "retention factor," which is equivalent to a 4D of 57.7%. This factor was deduced by having the subjects, who had their noses clipped shut, breathe through a two-way valve; the difference between inhaled and exhaled methanol concentrations was then measured.
Other investigators (21) exposed four subjects to 200 ppm methanol, the current allowable exposure threshold limit value (TLV) for workers (31) . Two different experiments measured subjects either at rest or during exercise. Ventilation was measured with a two-way non-rebreathing valve. These data are reproduced in Table  2 , along with the e that was required to fit the methanol inhalation model to these data. Although the difference in blood methanol concentrations at 6 hr between the exercise and resting groups was not statistically significant, the computed 1 indicated that fractional methanol absorption was much lower in the exercise group.
Mid-dose. Individual subjects were exposed to approximately 500 and 1000 ppm methanol for relatively short durations (approximately 2-5 hr) (13) . The observed blood methanol concentrations are compared to model predictions in Figure 3 . A different value of e was required to fit the data for each subject. The data from one subject, who weighed 57 kg, required eD = 0.79; the other subject, who weighed 78.5 kg, required 4) = 0.67-0.70.
Other investigators (32) exposed groups of 4 
Japan, some of whom were exposed sion analysis of blood or urine methanol (Fig. 4) . 
Discussion
The kinetic modeling at low-and middoses of methanol vapor in humans supports earlier findings in this laboratory in the rat and mouse: there is little, if any, difference in methanol disposition during and after methanol inhalation as compared to that after PO or IV administration. The model accurately predicted the decline in methanol blood concentration following removal of the monkey (32) or the human (22) Figure 4 . Comparison of the high-exposure methanol inhalation model (Eq. 1) to the data of methanolexposed Japanese workers (15) (16) (17) Table 2 ). This lack of effect of exposure concentration on tD in humans may be a consequence of the relatively low exposure concentrations. Alternatively, methanol in the humans may behave more like it does in the mice than in rats; in mice also was independent of exposure concentration (Perkins et al., submitted).
Some discussion of the decrease in between species with increasing body size (Table 2 ) is warranted. The high blood:air partitioning of water-soluble vapors predicts that such substrates should be absorbed completely upon inhalation. The most likely explanation of the less than 100% absorption of these substances (9) is the concept of "wash-in, wash-out" (33) . During inhalation, 100% of the inhaled water-soluble vapor is adsorbed on the lining of the upper respiratory tract (URT), and this adsorbed vapor diffuses away from the mucous lining toward the capillary blood. The diffusion process is relatively rapid but not instantaneous, so that the mucus lining still contains residual substrate when the exhaled air, devoid of substrate at the start of exhalation, re-entrains some residual substrate from the URT lining. The decrease in with increasing species size is paradoxical because the larger species breathe at a lower frequency (120, 70, and 15 breaths/min for the mouse, rat, and human, respectively). The lower breathing frequency would allow more time for the diffusion of the vapor away from the URT lining before start of exhalation, hence the fractional absorption should be higher in a slower-breathing species. One explanation for this apparent anomaly is that, normalized for body weight, the smaller species' URT must clean, warm, and humidify larger volumes of air (1.51, 0.52, and 0.15 L/min/kg in the mouse, rat, and human, respectively) in a shorter linear distance between nares and lungs. The biological requirements for more rapid heat and water vapor mass transfer in the smaller species may be a more important factor favoring overall mass transfer than the increased time for diffusion in the slower breathing, larger species. Table 3 illustrates two factors that are, in general, important for extrapolations used in methanol risk assessment. First, the increased ventilation per unit body weight associated with the smaller species leads to increasingly larger differences in the blood concentrations as inhaled vapor concentration increases. Ventilation per kilogram is 10-fold and 3.5-fold larger in mice and rats, respectively, than in humans; this difference is magnified because D in humans is lower than in rodents. The differences in blood methanol concentrations between species, however, are not that large, especially at lower exposure concentrations (<1000 ppm), highlighting the importance of an understanding of systemic kinetics: while the Vm. for methanol elimination is approximately comparable for the three species (120, 60, 96.6 mg/kg/hr in the mouse, rat, and human respectively), the Km differed by an order of magnitude (approximately 50 mg/L in rodents versus 460 mg/L in humans). After an 8-hr exposure at 1000 ppm, for example, the rodents metabolized methanol at 70-87% of V max (i.e., approaching saturation), while the human metabolized at about 8% of Vm..
The high-dose data from the methanolexposed Japanese workers (15-17) also raises questions regarding the use of the model for risk assessment. Using the model parameters that yielded a good fit of the low-and mid-dose data would substantially underpredict the high-dose data presented by these authors. The parameter values that would result in a better model fit were considered. The underprediction likely was not due to an underestimate of V in the model: because the subjects were not exposed to heavy exercise, the value of V used in the model was approximately 25% higher than the "at rest" estimates published in physiology texts (23) and slightly higher than that V reported for a mixture of light activities (24) . Moreover (27, 34) . If this were the case for susceptible workers exposed to methanol vapors, the implications for risk assessment are obvious. A worker exposed for 8 (20) . Indeed, this inhibition has been used for treatment of acute methanol toxicity, since ethanol slows the conversion of methanol to formate (1) . Furthermore, this inhibition is significant at relatively low doses of ethanol. The current recommended blood concentration of ethanol to treat methanol toxicity is 1000 mg/L (27) or 500 mg/L (1), which approximates intoxicating concentrations following alcohol consumption (800 mg/L is the definition of legal Figure 5B and C demonstrate the same ethanol regimen, with a 200 and 5000 ppm methanol exposure. The 200 ppm exposure shown in Figure 5B indicates that the 8-hr blood methanol concentrations predicted are approximately two-fold greater in the ethanol co-administration predictions, but are still low (less than 20 mg/L maximum) and return to approximately background each day. The SOOO ppm exposure with ethanol co-administration predictions shown in Figure SC are 42% and 62% higher than without the co-administration. The 8-hr 5000 ppm exposure with ethanol co-administration estimation (321-365 mg/L) approaches the 394 mg/L predicted for that exposure (16) .
The model developed (without ethanol co-administration, genetic deficiencies in ADH/ALDH, or other factors that reduce methanol metabolism) does not consider directly the time course of formate (the major metabolite of methanol), and it remains unclear whether it is the parent compound or the metabolite, or some combination of the two, which is responsible for the observed teratogenicity of methanol in laboratory rodents. In any case, the kinetics of the metabolite follow directly from the model, once the transfer of parent from the air into the blood is known. The present model provides that capability, and also illustrates some interesting concepts regarding inhalation toxicology. Consider Table 3 , using the proposed benchmark dose of 3078 ppm in the mouse for a 5% added risk of either exencephaly, cleft palate, or fetal resorption (4) . Applying a safety factor of 10 to the inhaled concentration for extrapolation between the mouse and the human indicates that a maximum allowable exposure concentration of 308 ppm would be required to protect humans from methanol teratogenicity. If one were to base the factor of safety on the blood concentration, Table 3 indicates that, for a 3078 ppm methanol vapor exposure, mice experience 12-to 18-fold higher blood methanol concentrations than humans. Thus, humans would already have a factor of safety of 13 to 18 at the same exposure concentration. However, considering the proposed benchmark dose for a 5% added risk of cervical rib defects in mice of 305 ppm, and assuming the same 10-fold safety factor, a maximal allowable exposure concentration of about 30 
